Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive testing and improved communication.
Gerard Silvestri, MD
Advertisement
Articles by Gerard Silvestri, MD
Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and education are vital for improvement.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Therapy Designation to T-DXd Early HER2+ BC
2
FDA Grants Breakthrough Therapy Status to JSKN003 for Advanced Ovarian Cancer
3
FDA Approves Subcutaneous Mosunetuzumab in Follicular Lymphoma
4
Pirtobrutinib Yields Promising Efficacy, Safety in R/R Follicular Lymphoma
5